<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Liang J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Metabolic reprogramming is a hallmark of cancer, including alterations in the hexosamine biosynthesis pathway (HBP). Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the key regulatory enzyme in the HBP; however, its role in invasive breast carcinoma remains underexplored.&lt;h4>Methods&lt;/h4>This study utilized integrated data from The Cancer Genome Atlas (TCGA) to assess GFPT1 expression in breast cancer (BRCA) patients. Functional enrichment and mutational landscape analyses were performed, along with chemosensitivity predictions. &lt;i>In vitro&lt;/i> experiments were conducted by silencing GFPT1 in malignant breast epithelial cells to evaluate changes in proliferation, migration, and apoptosis.&lt;h4>Results&lt;/h4>Elevated GFPT1 expression was linked to advanced-stage breas</pubmed_abstract><journal>Frontiers in genetics</journal><pagination>1482929</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11633769</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Bioinformatics insights into the role of GFPT1 in breast invasive carcinoma: implications for tumor prognosis, immune modulation, and therapeutic applications.</pubmed_title><pmcid>PMC11633769</pmcid><pubmed_authors>Yu C</pubmed_authors><pubmed_authors>Jia D</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Liang J</pubmed_authors><pubmed_authors>Fei T</pubmed_authors><pubmed_authors>Xiang Y</pubmed_authors><pubmed_authors>Duan F</pubmed_authors><pubmed_authors>Deng X</pubmed_authors><pubmed_authors>Ouyang M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bioinformatics insights into the role of GFPT1 in breast invasive carcinoma: implications for tumor prognosis, immune modulation, and therapeutic applications.</name><description>&lt;h4>Background&lt;/h4>Metabolic reprogramming is a hallmark of cancer, including alterations in the hexosamine biosynthesis pathway (HBP). Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the key regulatory enzyme in the HBP; however, its role in invasive breast carcinoma remains underexplored.&lt;h4>Methods&lt;/h4>This study utilized integrated data from The Cancer Genome Atlas (TCGA) to assess GFPT1 expression in breast cancer (BRCA) patients. Functional enrichment and mutational landscape analyses were performed, along with chemosensitivity predictions. &lt;i>In vitro&lt;/i> experiments were conducted by silencing GFPT1 in malignant breast epithelial cells to evaluate changes in proliferation, migration, and apoptosis.&lt;h4>Results&lt;/h4>Elevated GFPT1 expression was linked to advanced-stage breas</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-04-04T02:32:45.497Z</modification><creation>2025-04-04T02:32:45.497Z</creation></dates><accession>S-EPMC11633769</accession><cross_references><pubmed>39664728</pubmed><doi>10.3389/fgene.2024.1482929</doi></cross_references></HashMap>